What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Biologics

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1109356

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1109356

Europe Adalimumab Market - Industry Trends and Forecast to 2029

PUBLISHED: May 1, 2022

PAGES: 163 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

Europe adalimumab market is projected to register a substantial CAGR of 16.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Europe Adalimumab Market, By Indication (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa, Ulcerative Colitis, Chronic Plaque Psoriasis, Non-Infectious Intermediate and Others), Type (Biologics and Biosimilars), Dosage Strength (20MG/0.4MLG, 40MG/0.8MLG and Others), Drug Type (Branded), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, and Rest of Europe) Industry Trends and Forecast to 2029.

Some of the factors driving the growth of the Europe adalimumab market are:

Rise in prevalence of rheumatoid arthritis

Rise in geriatric population

Market Players:

The key market players for Europe adalimumab market are listed below:

AbbVie Inc.

Sandoz International GmbH

Amgen Inc.

Mylan N.V. (A subsidiary of Viatris)

Biogen

Celltrion Healthcare Co., Ltd.

Fresenius Kabi SwissBioSim GmbH

Alvotech

Biocad

Coherus BioSciences

Shanghai Henlius Biotech, Inc.

Synermore Biologics

Prestige BioPharma Ltd.

Janssen Global Services, LLC

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF EUROPE ADALIMUMAB MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 19

2 MARKET SEGMENTATION 21

2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 INDICATION LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32

4 PREMIUM INSIGHTS 35

4.1 PESTEL 36
4.2 PORTER'S FIVE FORCES MODEL 37

5 PIPELINE ANALYSIS 38

6 EPIDEMIOLOGY 39

7 EUROPE ADALIMUMAB MARKET: REGULATIONS 40

7.1 REGULATION IN EUROPE: 40

8 IMPACT OF BIOSIMILAR 42

9 IMPACT OF COVID-19 ON EUROPE ADALIMUMAB MARKET 43

9.1 OVERVIEW 43
9.2 ADALIMUMAB AND COVID-19 43
9.3 PRICE IMPACT OF COVID-19 43
9.4 IMPACT ON DEMAND 44
9.5 IMPACT ON SUPPLY CHAIN 44
9.6 STRATEGIC DECISIONS FOR MANUFACTURERS 44
9.7 CONCLUSION 45

10 MARKET OVERVIEW 46

10.1 DRIVERS 48
- 10.1.1 INCREASE IN PREVALENCE OF RHEUMATOID ARTHRITIS 48
- 10.1.2 INCREASE IN THE GERIATRIC POPULATION 48
- 10.1.3 INCREASE IN THE NUMBER OF CONTRACT RESEARCH ORGANIZATIONS 49
10.2 RESTRAINTS 49
- 10.2.1 HIGH COST OF DRUGS 49
- 10.2.2 SIDE EFFECTS OF DRUGS 50
- 10.2.3 CANCER-CAUSING DRUGS 50
10.3 OPPORTUNITIES 51
- 10.3.1 RISING HEALTHCARE EXPENDITURE 51
- 10.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 51
- 10.3.3 PRESENCE OF PRODUCT PIPELINE 52
10.4 CHALLENGES 52
- 10.4.1 LONG APPROVAL PROCEDURE 52
- 10.4.2 AVAILABILITY OF ALTERNATIVE DRUGS 53

11 EUROPE ADALIMUMAB MARKET, BY INDICATION 55

11.1 OVERVIEW 56
11.2 RHEUMATOID ARTHRITIS 59
11.3 ANKYLOSING SPONDYLITIS 59
11.4 CHRONIC PLAQUE PSORIASIS 60
11.5 CROHN'S DISEASE 60
11.6 ULCERATIVE COLITIS 60
11.7 PSORIATIC ARTHRITIS 61
11.8 JUVENILE IDIOPATHIC ARTHRITIS 61
11.9 HIDRADENITIS SUPPURATIVA 62
11.10 NON-INFECTIOUS INTERMEDIATE 62
11.11 OTHERS 63

12 EUROPE ADALIMUMAB MARKET, BY TYPE 64

12.1 OVERVIEW 65
12.2 BIOLOGICS 67
12.3 BIOSIMILARS 68
- 12.3.1 ADALIMUMAB-ATTO 68
- 12.3.2 ADALIMUMAB-ADAZ 68
- 12.3.3 ADALIMUMAB-FKJP 68
- 12.3.4 OTHERS 69

13 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH 70

13.1 OVERVIEW 71
13.2 40MG/0.8ML 73
13.3 20MG/0.4ML 74
13.4 OTHERS 74

14 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE 75

14.1 OVERVIEW 76
14.2 HUMIRA 78
14.3 AMGEVITA 78
14.4 IMRALDI 79
14.5 HYRIMOZ 79
14.6 YUFLYMA 79
14.7 HULIO 79
14.8 IDACIO 79

15 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE 80

15.1 OVERVIEW 81
15.2 ADULTS 83
15.3 CHILDREN 84

16 EUROPE ADALIMUMAB MARKET, BY END USER 85

16.1 OVERVIEW 86
16.2 HOSPITALS 88
16.3 SPECIALTY CLINICS 89
16.4 HOME HEALTHCARE 89
16.5 OTHERS 90

17 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL 91

17.1 OVERVIEW 92
17.2 HOSPITAL PHARMACIES 94
17.3 RETAIL PHARMACIES 95
17.4 ONLINE PHARMACIES 95
17.5 OTHERS 96

18 EUROPE 97

18.1 GERMANY 106
18.2 U.K. 108
18.3 ITALY 110
18.4 FRANCE 112
18.5 SPAIN 114
18.6 NETHERLANDS 116
18.7 SWITZERLAND 118
18.8 RUSSIA 120
18.9 BELGIUM 122
18.10 TURKEY 124
18.11 AUSTRIA 126
18.12 NORWAY 128
18.13 HUNGARY 130
18.14 LITHUANIA 132
18.15 IRELAND 134
18.16 POLAND 136
18.17 REST OF EUROPE 138

19 EUROPE ADALIMUMAB MARKET: COMPANY LANDSCAPE 139

19.1 COMPANY SHARE ANALYSIS: EUROPE 139

20 SWOT ANALYSIS 140

21 COMPANY PROFILE 141

21.1 ABBVIE INC. 141
- 21.1.1 COMPANY SNAPSHOT 141
- 21.1.2 REVENUE ANALYSIS 141
- 21.1.3 PRODUCT PORTFOLIO 142
- 21.1.4 RECENT DEVELOPMENTS 142

21.2 AMGEN INC. 143
- 21.2.1 COMPANY SNAPSHOT 143
- 21.2.2 REVENUE ANALYSIS 143
- 21.2.3 PRODUCT PORTFOLIO 144
- 21.2.4 RECENT DEVELOPMENT 144
21.3 BIOGEN 145
- 21.3.1 COMPANY SNAPSHOT 145
- 21.3.2 REVENUE ANALYSIS 145
- 21.3.3 PRODUCT PORTFOLIO 146
- 21.3.4 RECENT DEVELOPMENT 146
21.4 SANDOZ INTERNATIONAL GMBH 147
- 21.4.1 COMPANY SNAPSHOT 147
- 21.4.2 REVENUE ANALYSIS 147
- 21.4.3 PRODUCT PORTFOLIO 147
- 21.4.4 RECENT DEVELOPMENTS 147
21.5 CELLTRION HEALTHCARE CO., LTD. 148
- 21.5.1 COMPANY SNAPSHOT 148
- 21.5.2 REVENUE ANALYSIS 148
- 21.5.3 PRODUCT PORTFOLIO 149
- 21.5.4 RECENT DEVELOPMENTS 149
21.6 MYLAN N.V. (A SUBSIDIARY OF VAITRIS INC.) 150
- 21.6.1 COMPANY SNAPSHOT 150
- 21.6.2 REVENUE ANALYSIS 150
- 21.6.3 PRODUCT PORTFOLIO 151
- 21.6.4 RECENT DEVELOPMENTS 151
21.7 ALVOTECH 152
- 21.7.1 COMPANY SNAPSHOT 152
- 21.7.2 PRODUCT PORTFOLIO 152
- 21.7.3 RECENT DEVELOPMENT 152
21.8 BIOCAD 153
- 21.8.1 COMPANY SNAPSHOT 153
- 21.8.2 PRODUCT PORTFOLIO 153
- 21.8.3 RECENT DEVELOPMENTS 153
21.9 COHERUS BIOSCIENCES 154
- 21.9.1 COMPANY SNAPSHOT 154
- 21.9.2 PRODUCT PORTFOLIO 154
- 21.9.3 RECENT DEVELOPMENTS 154

21.10 FRESENIUS KABI SWISSBIOSIM GMBH 155
- 21.10.1 COMPANY SNAPSHOT 155
- 21.10.2 PRODUCT PORTFOLIO 155
- 21.10.3 RECENT DEVELOPMENTS 155
21.11 JANSSEN GLOBAL SERVICES, LLC 156
- 21.11.1 COMPANY SNAPSHOT 156
- 21.11.2 PRODUCT PORTFOLIO 156
- 21.11.3 RECENT DEVELOPMENTS 156
21.12 PRESTIGE BIOPHARMA LTD. 157
- 21.12.1 COMPANY SNAPSHOT 157
- 21.12.2 PRODUCT PORTFOLIO 157
- 21.12.3 RECENT DEVELOPMENT 157
21.13 SHANGHAI HENLIUS BIOTECH, INC. 158
- 21.13.1 COMPANY SNAPSHOT 158
- 21.13.2 PRODUCT PORTFOLIO 158
- 21.13.3 RECENT DEVELOPMENT 158
21.14 SYNERMORE BIOLOGICS 159
- 21.14.1 COMPANY SNAPSHOT 159
- 21.14.2 PRODUCT PORTFOLIO 159
- 21.14.3 RECENT DEVELOPMENTS 159

22 QUESTIONNAIRE 160

23 RELATED REPORTS 163

LIST OF TABLES

TABLE 1 EUROPE ADALIMUMAB MARKET, PIPELINE ANALYSIS 38
TABLE 2 BIOSIMILAR OF ADALIMUMAB APPROVED IN THE EUROPE 42
TABLE 3 ALTERNATIVE DRUG FOR INFLAMMATROY DISEASES TREATMENT 54
TABLE 4 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 58
TABLE 5 EUROPE ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 67
TABLE 6 EUROPE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 68
TABLE 7 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 73
TABLE 8 EUROPE BRANDED ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 78
TABLE 9 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 83
TABLE 10 EUROPE ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 88
TABLE 11 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 94
TABLE 12 EUROPE ADALIMUMAB MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 103
TABLE 13 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 103
TABLE 14 EUROPE ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
TABLE 15 EUROPE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
TABLE 16 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 104
TABLE 17 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 104
TABLE 18 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 104
TABLE 19 EUROPE ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 105
TABLE 20 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 105
TABLE 21 GERMANY ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 106
TABLE 22 GERMANY ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 106
TABLE 23 GERMANY BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 106
TABLE 24 GERMANY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 106
TABLE 25 GERMANY ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 107
TABLE 26 GERMANY ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 107
TABLE 27 GERMANY ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 107
TABLE 28 GERMANY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 107
TABLE 29 U.K. ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 108
TABLE 30 U.K. ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 108
TABLE 31 U.K. BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 108
TABLE 32 U.K. ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 108
TABLE 33 U.K. ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 109
TABLE 34 U.K. ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 109
TABLE 35 U.K. ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 109
TABLE 36 U.K. ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 109
TABLE 37 ITALY ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 110
TABLE 38 ITALY ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
TABLE 39 ITALY BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
TABLE 40 ITALY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 110
TABLE 41 ITALY ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 111
TABLE 42 ITALY ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 111
TABLE 43 ITALY ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 111
TABLE 44 ITALY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 111
TABLE 45 FRANCE ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 112
TABLE 46 FRANCE ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 112
TABLE 47 FRANCE BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 112
TABLE 48 FRANCE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 112
TABLE 49 FRANCE ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 113
TABLE 50 FRANCE ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 113
TABLE 51 FRANCE ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 113
TABLE 52 FRANCE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 113
TABLE 53 SPAIN ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 114
TABLE 54 SPAIN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 114
TABLE 55 SPAIN BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 114
TABLE 56 SPAIN ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 114
TABLE 57 SPAIN ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 115
TABLE 58 SPAIN ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 115
TABLE 59 SPAIN ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 115
TABLE 60 SPAIN ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 115
TABLE 61 NETHERLANDS ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 116
TABLE 62 NETHERLANDS ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 116
TABLE 63 NETHERLANDS BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 116
TABLE 64 NETHERLANDS ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 116
TABLE 65 NETHERLANDS ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 117
TABLE 66 NETHERLANDS ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 117
TABLE 67 NETHERLANDS ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 117
TABLE 68 NETHERLANDS ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 117
TABLE 69 SWITZERLAND ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 118
TABLE 70 SWITZERLAND ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 118
TABLE 71 SWITZERLAND BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 118
TABLE 72 SWITZERLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 118
TABLE 73 SWITZERLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 119
TABLE 74 SWITZERLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 119
TABLE 75 SWITZERLAND ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 119
TABLE 76 SWITZERLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 119
TABLE 77 RUSSIA ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 120
TABLE 78 RUSSIA ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 120
TABLE 79 RUSSIA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 120
TABLE 80 RUSSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 120
TABLE 81 RUSSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 121
TABLE 82 RUSSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 121
TABLE 83 RUSSIA ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 121
TABLE 84 RUSSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 121
TABLE 85 BELGIUM ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 122
TABLE 86 BELGIUM ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 122
TABLE 87 BELGIUM BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 122
TABLE 88 BELGIUM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 122
TABLE 89 BELGIUM ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 123
TABLE 90 BELGIUM ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 123
TABLE 91 BELGIUM ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 123
TABLE 92 BELGIUM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 123
TABLE 93 TURKEY ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 124
TABLE 94 TURKEY ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 124
TABLE 95 TURKEY BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 124
TABLE 96 TURKEY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 124
TABLE 97 TURKEY ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 125
TABLE 98 TURKEY ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 125
TABLE 99 TURKEY ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 125
TABLE 100 TURKEY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 125
TABLE 101 AUSTRIA ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 126
TABLE 102 AUSTRIA ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
TABLE 103 AUSTRIA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
TABLE 104 AUSTRIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 126
TABLE 105 AUSTRIA ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 127
TABLE 106 AUSTRIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 127
TABLE 107 AUSTRIA ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 127
TABLE 108 AUSTRIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 127
TABLE 109 NORWAY ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 128
TABLE 110 NORWAY ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
TABLE 111 NORWAY BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
TABLE 112 NORWAY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 128
TABLE 113 NORWAY ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 129
TABLE 114 NORWAY ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 129
TABLE 115 NORWAY ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 129
TABLE 116 NORWAY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 129
TABLE 117 HUNGARY ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 130
TABLE 118 HUNGARY ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
TABLE 119 HUNGARY BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
TABLE 120 HUNGARY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 130
TABLE 121 HUNGARY ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 131
TABLE 122 HUNGARY ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 131
TABLE 123 HUNGARY ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 131
TABLE 124 HUNGARY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 131
TABLE 125 LITHUANIA ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 132
TABLE 126 LITHUANIA ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 132
TABLE 127 LITHUANIA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 132
TABLE 128 LITHUANIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 132
TABLE 129 LITHUANIA ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 133
TABLE 130 LITHUANIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 133
TABLE 131 LITHUANIA ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 133
TABLE 132 LITHUANIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 133
TABLE 133 IRELAND ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 134
TABLE 134 IRELAND ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
TABLE 135 IRELAND BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
TABLE 136 IRELAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 134
TABLE 137 IRELAND ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 135
TABLE 138 IRELAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 135
TABLE 139 IRELAND ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 135
TABLE 140 IRELAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 135
TABLE 141 POLAND ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 136
TABLE 142 POLAND ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 136
TABLE 143 POLAND BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE, 2020-2029 (USD MILLION) 136
TABLE 144 POLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2020-2029 (USD MILLION) 136
TABLE 145 POLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 137
TABLE 146 POLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 137
TABLE 147 POLAND ADALIMUMAB MARKET, BY END USER, 2020-2029 (USD MILLION) 137
TABLE 148 POLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 137
TABLE 149 REST OF EUROPE ADALIMUMAB MARKET, BY INDICATION, 2020-2029 (USD MILLION) 138

LIST OF FIGURES

FIGURE 1 EUROPE ADALIMUMAB MARKET: SEGMENTATION 21
FIGURE 2 EUROPE ADALIMUMAB MARKET: DATA TRIANGULATION 23
FIGURE 3 EUROPE ADALIMUMAB MARKET: DROC ANALYSIS 24
FIGURE 4 EUROPE ADALIMUMAB MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 25
FIGURE 5 EUROPE ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 EUROPE ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 7 EUROPE ADALIMUMAB MARKET: DBMR MARKET POSITION GRID 28
FIGURE 8 EUROPE ADALIMUMAB MARKET: MARKET END USER COVERAGE GRID 29
FIGURE 9 EUROPE ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 10 EUROPE ADALIMUMAB MARKET: SEGMENTATION 34
FIGURE 11 THE RISING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE EUROPE ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 35
FIGURE 12 INDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ADALIMUMAB MARKET IN 2022 & 2029 35
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ADALIMUMAB MARKET 47
FIGURE 14 EUROPE ADALIMUMAB MARKET: BY INDICATION, 2021 56
FIGURE 15 EUROPE ADALIMUMAB MARKET: BY INDICATION, 2022-2029 (USD MILLION) 57
FIGURE 16 EUROPE ADALIMUMAB MARKET: BY INDICATION, CAGR (2022-2029) 57
FIGURE 17 EUROPE ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE 58
FIGURE 18 EUROPE ADALIMUMAB MARKET: BY TYPE, 2021 65
FIGURE 19 EUROPE ADALIMUMAB MARKET: BY TYPE, 2022-2029 (USD MILLION) 66
FIGURE 20 EUROPE ADALIMUMAB MARKET: BY TYPE, CAGR (2022-2029) 66
FIGURE 21 EUROPE ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE 67
FIGURE 22 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2021 71
FIGURE 23 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2022-2029 (USD MILLION) 72
FIGURE 24 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2022-2029) 72
FIGURE 25 EUROPE ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE 73
FIGURE 26 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, 2021 76
FIGURE 27 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 77
FIGURE 28 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2022-2029) 77
FIGURE 29 EUROPE ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE 78
FIGURE 30 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, 2021 81
FIGURE 31 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION) 82
FIGURE 32 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2022-2029) 82
FIGURE 33 EUROPE ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE 83
FIGURE 34 EUROPE ADALIMUMAB MARKET: BY END USER, 2021 86
FIGURE 35 EUROPE ADALIMUMAB MARKET: BY END USER, 2022-2029 (USD MILLION) 87
FIGURE 36 EUROPE ADALIMUMAB MARKET: BY END USER, CAGR (2022-2029) 87
FIGURE 37 EUROPE ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE 88
FIGURE 38 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2021 92
FIGURE 39 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 93
FIGURE 40 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 93
FIGURE 41 EUROPE ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 42 EUROPE ADALIMUMAB MARKET: SNAPSHOT (2021) 98
FIGURE 43 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2021) 100
FIGURE 44 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2022 & 2029) 100
FIGURE 45 EUROPE ADALIMUMAB MARKET: BY COUNTRY (2021 & 2029) 101
FIGURE 46 EUROPE ADALIMUMAB MARKET: BY INDICATION (2022-2029) 102
FIGURE 47 EUROPE ADALIMUMAB MARKET: COMPANY SHARE 2021 (%) 139

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ